Bavarian Nordic A/S

Chart & performance

D1W1MN

P/E

11.74

P/S

2.62

EPS

18.17

Div yield, %

—

Shrs. gr., 5y

7.62%

Rev. gr., 5y

27.21%

Revenues

Net income

CFO

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Bavarian Nordic A/S engages in the business of developing, manufacturing, and commercializing cancer immunotherapies and vaccines for infectious diseases. The firm is involved in cancer immunotherapy including cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian, and prostate cancer. The company was founded on July 1, 1992 and is headquartered in Hellerup, Denmark.

URL

https://www.bavarian-nordic.com/

IPO date

Nov 02, 1998

Employees

1,354

Domiciled in

Incorporated in

Valuation

No data to show